ZORYVE
Google image searchProduct monograph
Active ingredient
roflumilast, 0.3 %/W/W
DIN: 02552566
Dosage form(s): FOAM
Route(s) of administration: TOPICAL
Schedule: Prescription
Company: ARCUTIS CANADA, INC.
Date: 22-OCT-2024
ATC:
- D05 — ANTIPSORIATICS (ATC, ATC/DDD, )
- D05A — ANTIPSORIATICS FOR TOPICAL USE (ATC, ATC/DDD)
- D05AX — Other antipsoriatics for topical use (ATC, ATC/DDD)
- D05AX06 — ROFLUMILAST (ATC/DDD)
Reference brand drug: Zoryve
